$MBRX

Foster Jonathan P. purchased 293,333 shares of MBRX

Foster Jonathan P. (Chief Financial Officer) purchased 293,333 shares of Moleculin Biotech, Inc. (MBRX) on 2026-08-03.

Original reporting
SEC EDGAR · Foster Jonathan P.
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 3:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MBRX
Bullish
low confidence
Mentioned
$MBRX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MBRXBullishLow
01

Why it matters

The newest fact is the CFO’s open-market purchase of 293,333 shares on Aug. 3, with the filing submitted Aug. 5. The lack of disclosed price/value reduces tradable signal strength.

02

Market read

Traders may treat the filing as a mild bullish sentiment input, but it is unlikely to drive a major repricing without additional fundamental catalysts.

03

What to watch

The article does not state whether the purchase was part of any broader compensation or tax-related activity, and it provides no context on prior insider activity or company-specific news.

Relevance 4/10Novelty 5/10Timing: Form 4 filed Aug. 5, 2026, covering a purchase dated Aug. 3.

Background

This is an SEC Form 4 insider transaction disclosure for Moleculin Biotech, Inc. (MBRX).

Company-level read

Ticker impact

$MBRXBullishLow confidence
Context

Moleculin Biotech CFO Foster Jonathan P. bought 293,333 shares via an open-market Form 4 filed Aug. 5, 2026.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and small.

Evidence & confidence

The filing is primary-source and company-specific, but the article provides no disclosed transaction price, no 10b5-1 plan, and no accompanying fundamental catalyst.

Market effects

Minimal; single-insider transaction does not materially change biotech sector fundamentals.

None indicated.

None indicated.

Counterpoint

Insider buying may be routine diversification or personal liquidity planning, and without the disclosed price it is hard to infer conviction.

Key entities

  • Moleculin Biotech, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Foster Jonathan P.

    Chief Financial Officer who purchased 293,333 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MBRXMedAI 8/10

MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance

Moleculin Biotech (MBRX) shares dropped 25% after interim trial data for Annamycin in AML patients showed no statistical significance, though remission rates were higher than standard chemotherapy. The MIRACLE trial continues with 67 of 90 patients enrolled. The company has $10.317M in cash, expected to last until Q3 2026. CEO Klemp called results encouraging but noted more data is needed.

$MBRXMed

Moleculin's AML Trial Shows a Threefold Interim Remission Ad

Moleculin Biotech (Nasdaq: MBRX) reported preliminary unblinded interim efficacy from its MIRACLE pivotal AML trial on Aug. 14. In 45 patients, complete remission rates were 43% and 36% for Annamycin 190 and 230 mg/m² plus cytarabine versus 12% in control; composite CRc was 50% and 57% versus 29%. Company reported no cardiotoxicity to date and said cash was about $7.3M at June 30, 2026.

$MBRXMedAI 8/10

Moleculin Biotech, Inc. (MBRX): Results of Operations and Financial Condition

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial - Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML - MIRACLE trial ad

$MBRXMed

Moleculin reports promising preliminary phase II

Moleculin Biotech reported interim blinded Part A data from its MIRACLE Phase II/III trial of Annamycin plus cytarabine (AnnAraC) in relapsed or refractory AML. In 62 evaluable patients, CR was 24% and CRc 37%. Among 30 prior venetoclax-failure patients, results were in a harder-to-treat group. Part A has 74/90 enrolled, completion expected by Sep 2026, unblinded results Dec 2026-Feb 2027.

$MBRXHighAI 8/10

Moleculin Biotech Stock Is Sinking Friday: What's Going On? - Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech (NASDAQ:MBRX) priced a $9.3 million public stock offering at $0.75 per share, plus warrants, to fund clinical programs. Shares fell sharply on dilution concerns. In its MIRACLE trial, 62 evaluable patients showed 24% blinded complete remission and 37% composite complete remission. Recruitment reached 74 of 90 planned patients; full data unblinding expected Dec 2026 to Feb 2027.